Present and Future Roles of FDG-PET/CT Imaging in the Management of Malignant Pleural Mesothelioma

Overview

Journal Jpn J Radiol

Publisher Springer

Specialty Radiology

Date 2016 May 26

PMID 27222020

Citations 7

Authors

Kazuhiro Kitajima

Hiroshi Doi

Kozo Kuribayashi

Affiliations

Soon will be listed here.

Abstract

Positron emission tomography/computed tomography (PET/CT) integrated with 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) has emerged as a powerful tool for combined metabolic and anatomic evaluations in clinical oncologic imaging. This review discusses the utility of (18)F-FDG PET/CT as a tool to manage patients with malignant pleural mesothelioma. We discuss different stages of patient management in malignant pleural mesothelioma, including diagnosis, initial staging, therapy planning, early treatment response assessment, re-staging, and prognosis.

Citing Articles

Clinical Significance of Bone Metastases in Pleural Mesothelioma.

Miyake M, Kuribayashi K, Doi H, Kubota A, Otuski T, Negi Y Thorac Cancer. 2025; 16(5):e70033.

PMID: 40066587 PMC: 11894435. DOI: 10.1111/1759-7714.70033.

The Prognostic Value of F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review.

Taralli S, Giancipoli R, Caldarella C, Scolozzi V, Ricciardi S, Cardillo G J Clin Med. 2022; 11(1).

PMID: 35011772 PMC: 8745748. DOI: 10.3390/jcm11010033.

Implementing CT tumor volume and CT pleural thickness into future staging systems for malignant pleural mesothelioma.

Lauk O, Patella M, Neuer T, Battilana B, Frauenfelder T, Nguyen-Kim T Cancer Imaging. 2021; 21(1):48.

PMID: 34344472 PMC: 8330125. DOI: 10.1186/s40644-021-00415-5.

A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion.

Gu R, Jiang L, Duan T, Chen C, Wu S, Mu D Onco Targets Ther. 2021; 14:4231-4237.

PMID: 34295165 PMC: 8291962. DOI: 10.2147/OTT.S315869.

Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis.

Kitajima K, Matsuo H, Kono A, Kuribayashi K, Kijima T, Hashimoto M Oncotarget. 2021; 12(12):1187-1196.

PMID: 34136087 PMC: 8202770. DOI: 10.18632/oncotarget.27979.

References

Wang Z, Reddy G, Gotway M, Higgins C, Jablons D, Ramaswamy M . Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004; 24(1):105-19. DOI: 10.1148/rg.241035058. View

Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T, Bartsch P . Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest. 2004; 125(2):489-93. DOI: 10.1378/chest.125.2.489. View

Wilcox B, Subramaniam R, Peller P, Aughenbaugh G, Nichols Iii F, Aubry M . Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer. 2009; 10(4):244-8. DOI: 10.3816/CLC.2009.n.033. View

Heelan R, Rusch V, Begg C, Panicek D, Caravelli J, Eisen C . Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol. 1999; 172(4):1039-47. DOI: 10.2214/ajr.172.4.10587144. View

Larson S, Erdi Y, Akhurst T, Mazumdar M, Macapinlac H, Finn R . Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging. 2003; 2(3):159-171. DOI: 10.1016/s1095-0397(99)00016-3. View

Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A . Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. Oncol Rep. 2011; 27(2):333-8. DOI: 10.3892/or.2011.1520. View

Benard F, Sterman D, Smith R, Kaiser L, Albelda S, Alavi A . Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999; 40(8):1241-5. View

Roca E, Laroumagne S, Vandemoortele T, Berdah S, Dutau H, Maldonado F . 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough. Lung Cancer. 2012; 79(2):187-90. DOI: 10.1016/j.lungcan.2012.10.017. View

Rusch V . A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995; 108(4):1122-8. DOI: 10.1378/chest.108.4.1122. View

10.

Cheng L, Tunariu N, Collins D, Blackledge M, Riddell A, Leach M . Response evaluation in mesothelioma: Beyond RECIST. Lung Cancer. 2015; 90(3):433-41. DOI: 10.1016/j.lungcan.2015.08.012. View

11.

Terada T, Tabata C, Tabata R, Okuwa H, Kanemura S, Shibata E . Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma. Exp Ther Med. 2012; 4(2):197-200. PMC: 3460268. DOI: 10.3892/etm.2012.572. View

12.

Gerbaudo V, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker D . FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging. 2011; 38(5):810-21. DOI: 10.1007/s00259-010-1704-x. View

13.

Erasmus J, Truong M, Smythe W, Munden R, Marom E, Rice D . Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005; 129(6):1364-70. DOI: 10.1016/j.jtcvs.2004.10.034. View

14.

Nickell Jr L, Lichtenberger 3rd J, Khorashadi L, Abbott G, Carter B . Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics. 2014; 34(6):1692-706. DOI: 10.1148/rg.346130089. View

15.

Sugarbaker D, Flores R, Jaklitsch M, Richards W, Strauss G, Corson J . Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1998; 117(1):54-63; discussion 63-5. DOI: 10.1016/s0022-5223(99)70469-1. View

16.

Gerbaudo V, Sugarbaker D, Britz-Cunningham S, Di Carli M, Mauceri C, Treves S . Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002; 43(9):1144-9. View

17.

Ceresoli G, Chiti A, Zucali P, Rodari M, Lutman R, Salamina S . Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol. 2006; 24(28):4587-93. DOI: 10.1200/JCO.2006.06.8999. View

18.

Carretta A, Landoni C, Melloni G, Ceresoli G, Compierchio A, Fazio F . 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Eur J Cardiothorac Surg. 2000; 17(4):377-83. DOI: 10.1016/s1010-7940(00)00377-8. View

19.

Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N . Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012; 48(8):1244-54. DOI: 10.1016/j.ejca.2012.01.016. View

20.

Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C . Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm. 2004; 19(2):149-54. DOI: 10.1089/108497804323071913. View